WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca PLC Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Astrazeneca earnings were $8.3B for the trailing 12 months ending Jun 30, 2025, with 28.6% growth year over year. The latest AZN earnings report on Jun 30, 2025 announced Q2 2025 earnings of $2.5B, down 16% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AZN reported annual earnings of $7.0B, with 18.1% growth. The next AZN earnings date is Nov 6, 2025.

AZN past earnings growth

How has AZN's earnings growth performed historically?

Company
28.61%
Industry
49.61%
Market
34.06%
AZN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AZN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AZN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AZN earnings history

Current Revenue
$56.5B
Current Earnings
$8.3B
Current Profit Margin
14.7%
AZN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

AZN Return on Equity

Current Company
19.8%
Current Industry
60%
Current Market
30.7%
AZN's Return on Equity (19.8%)... subscribe to Premium to read more.
High Return on Equity Performance

AZN undefined

Current Company
7.8%
Current Industry
10.6%
AZN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AZN announces earnings.

AZN undefined

Current Company
14.82%
Current Industry
18.3%
AZN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AZN vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AZN$18.51B$8.30B+26.68%$2.68
NVS$27.72B$13.65B+16.64%$6.91
MRK$25.03B$16.41B+9.49%$6.50
AMGN$15.89B$6.62B-0.02%$12.32
GILD$10.97B$6.31B+5.22%$5.05
View Top General Drug Manufacturer Stocks

AZN earnings dates

Next earnings date
Nov 6, 2025

Astrazeneca Earnings Reports & History FAQ

What were Astrazeneca's earnings last quarter?

On AZN's earnings call on Invalid Date, Astrazeneca (NASDAQ: AZN) reported Q2 2025 earnings per share (EPS) of $0.79, up 27.42% year over year. Total AZN earnings for the quarter were $2.45 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.62.

If you're new to stock investing, here's how to buy Astrazeneca stock.

When does Astrazeneca report earnings?

The next AZN earnings date is Invalid Date. Add AZN to your watchlist to be reminded of Astrazeneca's next earnings date.

Is Astrazeneca profitable or losing money?

As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $8.30 billion, a 28.8% increase year over year.

What was AZN's earnings growth in the past year?

As of Astrazeneca's earnings date in Invalid Date, Astrazeneca's earnings has grown 28.61% year over year. This is 21 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 49.61%. AZN earnings in the past year totalled $8.30 billion.

What are Astrazeneca's earnings expectations?

The current EPS estimate for Astrazeneca's earnings report in Invalid Date is $1.14.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.